Изучение механизмов активации васкулярного эндотелия у больных псориазом и артериальной гипертензией

G. I. Makurina

doi:10.14739/2310-1210.2016.1.64070

Authors

G. I. Makurina Zaporizhzhia State Medical University, https://orcid.org/0000-0002-3293-2748

DOI:

https://doi.org/10.14739/2310-1210.2016.1.64070

Keywords:

Vascular Endothelial Growth Factor-A, Psoriasis, Essential Hypertension

Abstract

The aim. To study Vascular Endothelial Growth Factor-A expression in patients with both psoriasis and hypertension.

Methods and results. 102 patients were included. Vascular Endothelial Growth Factor-A level was detected with indirect ELISA method.

It was found that VEGF-A level was maximal in patients with psoriasis and hypertension stage II - 694.44 (567.36–829.87) pg/ml. That was statistically significantly higher (p<0,01) than in patients with psoriasis and more than 5 times (p<0,01) higher than VEGF-A levels patients with essential hypertension.

At the same time, vascular endothelial growth factor level in patients with psoriasis without essential hypertension was higher in 3.5 times (p<0,01) when compared with group of patients with essential hypertension, which did not exceed 300 pg/ml. This indicates it is most active angiogenesis in patients with a combination of psoriasis and essential hypertension.

Conclusion. The results indicated the direct relationship between the reliable indicators of VEGF-A expression and dermatosis clinical course severity in patients with both psoriasis and essential hypertension.

References

Kubanova, A. A., Nikolas, J. F., Puig, L., Prince, J., Katunina, O. R., & Znamenskaya, L. F. (2010) Immunnye mekhanizmy psoriaza. Novye strategii biologicheskoj terapii [Immune mechanisms of psoriasis. New strategies of biotherapy]. Vestnik dermatologii i venerologii, 1, 35–47. [in Russian].

Gisondi, P., Del Giglio, M., Cozzi, A., & Girolomoni, G. (2010) Psoriasis, the liver, and the gastrointestinal tract. Dermatol. Ther., 23(2), 155–159. doi: 10.1111/j.1529-8019.2010.01310.x.

Boehncke, W. H., & Boehncke, S. (2008) Research in practice: the systemic aspects of psoriasis. J. Dtsch. Dermatol. Ges., 6, 622–625. doi: 10.1111/j.1610-0387.2008.06785.x.

Sukharev, A. V., Nazarov, R. N., Yurchik, M. I., & Patrushev, A. V. (2009) Vul′garnyj psoriaz: osobennosti patogeneza i terapii [Psoriasis vulgaris: the specific features of its pathogenesis and therapy]. Rossijskij zhurnal kozhnykh i venericheskikh boleznej, 2, 23–26. [in Russian].

Mak, R. K., Hundhausen, S., & Nestle, F. O. (2009) Progress in understanding the immunopathogenesis of psoriasis. ActasDermo-Sifiliograficas, 100(2), 2–13.

Kurdina, M. I., & Makarenko, L. A. (2009) Kompleksnaya ocenka bezopasnosti lecheniya bol′nykh psoriazom khimernymi monoklonal′nymi antitelami k FNO-a [Integrated Safety Assessment of treatment of psoriasis patients with chimeric monoclonal antibody to TNF-alpha]. Abstracts of Papers of the 3rd All-Russian Congress of dermatologists, (S. 45). Moscow. [in Russian].

Gisondi, P., Giglio, M. D., Cozzi, A., & Girolomoni, G. (2010) Psoriasis, the liver, and the gastrointestinal tract. Dermatolodic Therapy., 23(2), 155–159. doi: 10.1111/j.1529-8019.2010.01310.x.

Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P., & Nast, A. (2009) European S3-Guidelines on the systemic treatment of psoriasis vulgaris. JEADV, 23(2), 70. doi: 10.1111/j.1468-3083.2009.03389.x.

Peternel, S., & Kastelan, M. (2009) Immunopathogenesis of psoriasis: focus on natural killer T cells. J. Eur. Acad. Dermatol. Venereol., 23(10), 1123–1127. doi: 10.1111/j.1468-3083.2009.03292.x.

Yan, K. X., Fang, X., Han, L., Zhang, Z. H., Kang, K. F., Zheng, Z. Z., & Huang, Q. (2010) Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br. J. Dermatol, 163, 48–56. doi: 10.1111/j.1365-2133.2010.09742.x.

Dzherieva, I. S., & Volkova, N. I. (2010) Arterial′naya gipertenziya i metabolicheskie narusheniya [Arterial hypertension and metabolic disorders]. Klinicheskaya medicina, 88(2), 4–8. [in Russian].

Bunova, S. S. (2009) Vklad nejrogumoral′noj disfunkcii i povyshennoj massy tela v techenie gipertonicheskoj bolezni [Contribution of neurohumoral dysfunction and overweight to the course of essential hypertension]. Terapevticheskij arkhiv, 81(5), 71–74. [in Russian].

Drobotya, N. V., Doltmurzieva, N. S., Gusejnova, E′. Sh., & Drobotya, A. A. (2010) E′ffekty gipotenzivnoj terapii na sostoyanie sosudistoj stenki u bol′nykh arterial′noj gipertoniej [The effects of antihypertensive therapy on the vascular wall in hypertensive patients]. Klinicheskaya farmakologiya i terapiya, 19(4), 30–32. [in Russian].

Coleman, S. K., Möykkynen, T., Hinkkuri, S., Vaahtera, L., Korpi, E. R., Pentikäinen, O. T., & Keinänen, K. (2010) Ligand-binding domain determines endoplasmic reticulum exit of AMP A receptors. J. Biol. Chem., 285(46), 36032–36039. doi: 10.1074/jbc.M110.156943.

Borselli, C., Storrie, H., Benesch-Lee, F., Shvartsmana, D., Cezara, C., Lichtmane, J. W., et al. (2010) Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. ProcNatlAcadSci USA, 107(8), 3287–92. doi: 10.1073/pnas.0903875106.

Beohar, N., Rapp, J., Pandya, S., & Losordo, D. W. (2010) Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am CollCardiol, 56(16), 1287–97. doi: 10.1016/j.jacc.2010.05.039.

Anderson, K. S., Petersson, S., Wong, J., Shubbar, E, Lokko, N. N., Carlström, M., & Enerbäck, C. (2010) Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br. J. Dermatol., 163(5), 1085–89. doi: 10.1111/j.1365-2133.2010.09990.x.

Matushevskaya, Yu. I. (2009) Ocenka e′ffektivnosti terapii bol′nykh tyazhelymi formami psoriaza s primeneniem genno-inzhenernogo biologicheskogo preparata infliksimab na osnovanii klinicheskikh i immunologicheskikh pokazatelej (Avtoref. dis …kand. med. nauk). [Estimation of efficiency treatment of patients with severe psoriasis with the use of genetically engineered biological drug infliximab based on clinical and immunological parameters]. (Extended abstract of candidate’s thesis). Moscow. [in Russian].

Patel, R. V., Clark, L. N., Lebwohl, M., & Weinberg, J. M. (2009) Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol, 60, 100–117. doi: 10.1016/j.jaad.2008.12.031.

Li, Y., Liao, W., Chang, M., Schrodi, S. J., Bui, N., Catanese, J J., et al. (2009) Further genetic evidence for three psoriasis risk genes: ADAM33, CDKAL1, and PTPN22. J. Invest. Dermatol, 129, 629–34. doi: 10.1038/jid.2008.297.

Ketlinskij, S. A., & Simbircev, A. S. (2008) Citokiny [Cytokines]. Saint Petersburg: Foliant. [in Russian].

Myung, S. J., Yoon, J. H., Kim B. H. Lee, J. H., Jung, E. U., & Lee, H. S. (2009) Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. J Pharmacol ExpTher., 330(1), 276–282. doi: 10.1124/jpet.109.151860.